Equities Analysts Set Expectations for EYPT FY2025 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a research note issued on Thursday, March 6th. Cantor Fitzgerald analyst J. Kim now anticipates that the company will earn ($2.96) per share for the year, down from their previous forecast of ($2.49). The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million.

A number of other analysts have also weighed in on the company. Chardan Capital restated a “buy” rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Citigroup initiated coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, EyePoint Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $26.63.

EyePoint Pharmaceuticals Stock Up 3.7 %

EyePoint Pharmaceuticals stock opened at $7.35 on Monday. The business has a fifty day moving average of $7.25 and a two-hundred day moving average of $8.43. The firm has a market cap of $501.64 million, a P/E ratio of -3.68 and a beta of 1.41. EyePoint Pharmaceuticals has a twelve month low of $5.54 and a twelve month high of $23.97.

Institutional Trading of EyePoint Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 16.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company’s stock valued at $9,583,000 after purchasing an additional 166,699 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of EyePoint Pharmaceuticals by 5.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock valued at $1,141,000 after acquiring an additional 7,967 shares during the period. Barclays PLC increased its position in shares of EyePoint Pharmaceuticals by 410.4% in the 3rd quarter. Barclays PLC now owns 245,045 shares of the company’s stock valued at $1,959,000 after acquiring an additional 197,033 shares during the period. JPMorgan Chase & Co. increased its position in shares of EyePoint Pharmaceuticals by 1,171.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company’s stock valued at $2,970,000 after acquiring an additional 342,516 shares during the period. Finally, Franklin Resources Inc. increased its position in shares of EyePoint Pharmaceuticals by 9.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock valued at $32,056,000 after acquiring an additional 362,399 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.